EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study

NCT00216255 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Persistent Developmental Stuttering

Interventions

DRUG: Pagoclone
DRUG: Placebo

Sponsor

Endo Pharmaceuticals